About HLA class II histocompatibility antigen, DQ beta 2 chain
HLA class II histocompatibility antigen, DQ beta 2 chain (HLA-DQB2) is a protein
from Homo sapiens identified by UniProt accession
P05538, 268 residues long.
MolForge cross-references it against 0 known binders and
267 disease associations.
Target properties
| Protein name | HLA class II histocompatibility antigen, DQ beta 2 chain |
|---|
| UniProt accession | P05538 |
|---|
| Gene | HLA-DQB2 |
|---|
| Organism | Homo sapiens |
|---|
| Length | 268 residues |
|---|
| Molecular weight | — |
|---|
| EC numbers | — |
|---|
| Target class | UNCLASSIFIED |
|---|
| Subcellular location | — |
|---|
| Keywords | — |
|---|
Druggability
Target tractability assessment (Open Targets + pocket analysis). No approved drug
| Druggability tier | MEDIUM |
|---|
| Druggability score | — |
|---|
| Pocket score | — |
|---|
| Max clinical phase | — |
|---|
Disease associations (267)
Diseases linked to this target (Open Targets).
- chronic hepatitis B virus infection · score 0.35
- hepatitis B virus infection · score 0.33
- systemic lupus erythematosus · score 0.24
- diabetic retinopathy · score 0.20
- endometrial cancer · score 0.18
- thyroid gland adenocarcinoma · score 0.18
- ACPA-positive rheumatoid arthritis · score 0.18
- diastolic blood pressure · score 0.17
- smoking status measurement · score 0.17
- proliferative diabetic retinopathy · score 0.15
3D Structure (1)
Experimental (PDB) and predicted (AlphaFold) structures for this protein.
| Structure | Source | Method | Mean pLDDT | Resolution (Å) |
|---|
| AF-P05538-F1 | alphafold | PREDICTED | 86.34 | — |
Amino-acid sequence (268 residues)
MSWKMALQIP GGFWAAAVTV MLVMLSTPVA EARDFPKDFL VQFKGMCYFT NGTERVRGVA RYIYNREEYG RFDSDVGEFQ AVTELGRSIE DWNNYKDFLE QERAAVDKVC RHNYEAELRT TLQRQVEPTV TISPSRTEAL NHHNLLVCSV TDFYPAQIKV RWFRNDQEET AGVVSTSLIR NGDWTFQILV MLEITPQRGD IYTCQVEHPS LQSPITVEWR AQSESAQSKM LSGIGGFVLG LIFLGLGLII RHRGQKGPRG PPPAGLLH
Explore HLA class II histocompatibility antigen, DQ beta 2 chain with MolForge
Find binders, run structure-based screening, and map this target across
diseases and approved drugs with our AI-powered platform.
Browse all targets